The Anti-Bacterial segment includes few of the oldest classes of drugs that have enriched the industry over past several decades. With over 80% of the total market share being held by generics, the major brands hold a small percentage of shares in the market. In 2014, the global anti-bacterial drugs market was valued at US$ 43,444.9 million and is anticipated to grow to US$ 49,871.0 million by 2019 at a CAGR of 3.1%. Over the past two decades, there has been a significant rise of drug resistance among humans. MRSA and other drug resistant superbugs and microbes have always been a challenge for the pharmaceutical companies. In the face of rising incidence of hospital and community acquired bacterial diseases, the market for antibacterials as a whole is expected to benefit. As compared to the last decade, companies such as Cubist and Cempra are leading the way in introducing anti-bacterials posed to combat the challenges of drug resistant super bugs. At least 39 anti-bacterial compounds are undergoing clinical trials across a variety of classes, with 25 of these in phase 2 or 3 clinical trials, and 3 compounds under review at the FDA. There had been no new classes of anti-bacterial drugs for almost thirty years, however a latest article researchers have discovered a new drug, called teixobactin, which marks the launch of a new class of antibiotics.
Market Drivers:
- Increasing incidence of hospital and community acquired bacterial infections pushing growth of brands and generics Improving
- Legal Framework for provision of Incentives expected to drive growth
Market Inhibitors:
- Limited pipeline drugs and absence of new indication targets may lead to significant erosion against generics
Free Sample Report@ http://www.sa-brc.com/Global-Anti-Bacterial-Drugs-Market-Assessment–Forecast-2015-2019/sample2
Current Drugs Covered In This Report:
- Cubicin
- Teflaro/Zinforo
- Dificid
- Dalvance
- Orbactiv
- Sivextro
- Zerbaxa
- Avycaz
- Zyvox
- Avelox
- Augmentin
- Zosyn/Tazocin
- Invanz
- Tygacil
Pipeline Drugs Covered In This Report:
- Surotomycin
- Solithromycin
- Delafloxacin
- Plazomycin
- Taksta
- Cadazolid
- Carbavance
- Eravacycline
Click For Full Report@ http://www.sa-brc.com/report/Global-Anti-Bacterial-Drugs-Market-Assessment–Forecast-2015-2019/2
Key Players Covered In This Report:
- Actavis Pharmaceuticals
- Astrazeneca
- Cempra Pharmaceuticals
- Cubist Pharmaceuticals
- Durata Therapeutics
- Forest Laboratories
- GlaxoSmithKline (GSK)